Biomoda and Amigenics collaborate to advance treatments for lung and other cancer

Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) and Advanced Medical Imaging and Genetics (Amigenics) (www.amigenics.com), an innovative medical clinic specializing in prevention and early detection of disease, announced their intent to collaborate on a variety of projects to advance technology for the early detection of lung and other cancer.

“Amigenics is at the forefront of individualized health care using state-of-the-art imaging and diagnosis”

“Amigenics is at the forefront of individualized health care using state-of-the-art imaging and diagnosis,” said John Cousins, President of Biomoda. “We are excited about the prospect of collaborating with them and strengthening both companies.”

Amigenics’ staff of physicians and genetic counselors offer personalized disease risk screening, clinical evaluations, genetic counseling and treatment plans for a variety of conditions that affect adults. Amigenics’ Las Vegas, Nevada, clinic combines comprehensive medical evaluations with the revolutionary technologies of advanced medical imaging and genetics.

Cousins said the two companies will pursue initiatives that complement their businesses. Biomoda is seeking Food and Drug Administration (FDA) approval of its cytology-based screening technology as a Class III medical device. Multi-site Phase III trials, the final step before FDA approval, are scheduled to begin in 2010.

“I anticipate that our Phase III trials will incorporate a variety of advancements in the methods of collection, data correlation, and imaging due to our collaboration with Amigenics,” said Cousins. “We always are looking to partner with companies leading the pack, and Amigenics certainly is a leader.”

Source: Biomoda